ASND vs. CERE, LEGN, VKTX, JAZZ, ITCI, CYTK, ELAN, ROIV, BPMC, and IONS
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Blueprint Medicines (BPMC), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.
Ascendis Pharma A/S presently has a consensus target price of $176.88, suggesting a potential upside of 44.04%. Cerevel Therapeutics has a consensus target price of $42.67, suggesting a potential upside of 0.75%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Cerevel Therapeutics.
In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 9 mentions for Cerevel Therapeutics. Cerevel Therapeutics' average media sentiment score of 0.89 beat Ascendis Pharma A/S's score of 0.38 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.
Cerevel Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S.
Cerevel Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -152.68%. Cerevel Therapeutics' return on equity of -98.94% beat Ascendis Pharma A/S's return on equity.
Ascendis Pharma A/S has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Ascendis Pharma A/S received 255 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 65.50% of users gave Ascendis Pharma A/S an outperform vote.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Cerevel Therapeutics beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
